PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
DelveInsight

Press Release


Receive press releases from DelveInsight: By Email RSS Feeds:

Antibody Drug Conjugate Insight: Technology Trend, Pipeline Assessment and Competitive Landscape, 2016


DelveInsight has added a new report “Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016” to its Portfolio.

New Delhi, India, May 14, 2016 --(PR.com)-- The Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the client with details on the ongoing enterprises and the upcoming business opportunities related to new interventions.

It comprehensively includes:

· 215+ products and 50+ different technologies along with 70+ companies actively involved in drug development. There are 5 drugs in phase III, 22 in phase II, 42 in phase I, and 87 in pre-clinical, 28 in discovery, 16 dormant and 19 discontinued drugs.
· Brentuximab Vedotin, developed by Seattle Genetics, is the leading product.
· R&D activities and technologies used along with the pipeline molecules in development.
· Therapeutic assessments by molecule types, route of administration, monotherapy and combination products.
· Information related to collaborations, in-licensing and out-licensing deals.

DelveInsights, Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report provides the in-depth analysis of Antibody Drug Conjugate Landscape across the globe. Therefore the report on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provide information on chemical, technology information and comparative analysis at various stages. In addition, it helps to identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 2950 as a single user license, USD 5900 as a site license and USD 8850 as a Global/Enterprise License.

For more information on Antibody Drug Conjugate Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape, 2016 report, email at info@delveInsight.com.

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm. They help clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.
Contact Information
DelveInsight
Krati Agarwal
+91-11-4568 9769
Contact
www.delveinsight.com

Click here to view the list of recent Press Releases from DelveInsight
Promote Your Business